

# Transforming Urologic Care in Philadelphia and Worldwide.

## The Fox Chase – Temple Urologic Institute.



Founding Director, Fox Chase – Temple Urologic Institute, Robert Uzzo, MD, MBA, FACS, President & CEO, Fox Chase (center); Co-Executive Directors Alexander Kutikov, MD, FACS, Chair, Department of Urology, Fox Chase (l); Jay Simhan, MD, FACS, Chair, Department of Urology at Temple University Hospital (r)

In just four years, the Fox Chase – Temple Urologic Institute has leveraged the expertise of two renowned institutions to deliver an exceptionally broad range of aligned and specialized urology and urologic oncology services, led by eminent clinicians and thought leaders.

**#1** in Pennsylvania for kidney cancer and bladder cancer surgical volumes.\*

The Institute combines the depth of expertise of Fox Chase Cancer Center—an NCI-designated Comprehensive

Cancer Center—with the resources of Temple Health, a leading academic health system with a long-standing urology program that performs thousands of procedures each year across the full spectrum of urologic conditions.

The Institute offers easy access to an unprecedented level of comprehensive urologic care from globally recognized specialists. Fox Chase also provides access to advanced treatments and novel clinical trials as well as a smooth transition to integrated urologic oncology and radiation oncology, rapidly drawing patients from the Philadelphia region, the country, and abroad.

\*Pennsylvania Hospitals and Ambulatory Surgical Center 2025 data

### Urologic Institute Leaders: OR, Clinic, Bench, and Bedside

- The Institute's **extensive surgical options** include robotics, focal therapy, and complex open procedures.
- **International experts** offer urethral reconstruction, penile prosthetics, intra-abdominal reconstructions, and female pelvic reconstruction.
- **Elite residency and fellowship programs** train future leaders.
- **Globally recognized** for **expertise** in kidney cancer, bladder cancer, and interstitial cystitis.
- One of the **country's largest bladder preservation programs** through light cystoscopy (Cysview) and intravesical therapy.
- **Inventor** of the seminal **R.E.N.A.L Nephrometry** score to categorize renal masses.
- At the **forefront** of **bladder preservation trials** such as RETAIN and INSITE.



Fox Chase  
Cancer Center  
Temple Health

The Urologic Institute

# Explore Fox Chase Genitourinary Clinical Trials

## Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)

**Investigator:** Alexander Kutikov, MD, FACS **ClinicalTrials.gov ID:** NCT06396533

This trial aims at investigating the diagnostic ability of a combined diagnostic panel including systematic endoscopic evaluation (SEE), blood-based ctDNA assay, and urine-based cfDNA assay to predict the presence of residual tumor remaining in the bladder at cystectomy.



## Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy (GAIN-BCG)

**Investigator:** Andres F. Correa, MD **ClinicalTrials.gov ID:** NCT07000084

This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette-Guérin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvement (recurrent).



## Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART)


**Investigator:** Mark A Hallman, MD, PhD **ClinicalTrials.gov ID:** NCT07219303

The goal of this clinical trial is to evaluate whether adaptive stereotactic body radiation therapy (SBRT) is a safe and effective way to treat prostate cancer in adults. It will assess the safety profile of adaptive SBRT over time.




### Fox Chase Cancer Nomograms: Cutting-Edge Predictive Disease Modeling

What is the likelihood of a patient's kidney, testicular, or prostate cancer recurring? Fox Chase Cancer Nomograms utilize multiple-site, disease-specific data to predict the likelihood of a specific outcome based on research from top scientific publications.



[Learn About Nomograms](#)



### HOW TO REFER

To refer a patient, please call **888-FOX-CHASE (888-369-2427)** or visit [FoxChase.org/Refer](https://www.foxchase.org/Refer).

### CONTACT OUR TEAM

Our Key Account Managers can offer a seamless introduction to our specialists, obtain a patient appointment, and answer any questions or concerns you have. Contact our team at [KeyAccountManager@fcc.edu](mailto:KeyAccountManager@fcc.edu).



The Urologic Institute

Non-discrimination notice: It is the policy of Fox Chase Cancer Center and Temple University Hospital, Inc., that no one shall be excluded from or denied the benefits of or participation in the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

© Fox Chase Cancer Center. All rights reserved. 5/26

[FoxChase.org](https://www.foxchase.org)